Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Illustration: Aïda Amer/Axios
The Trump administration is plowing ahead on drug prices, hoping to break through the cycle of legal and political setbacks that have stymied the rest of its health care agenda.
The big picture: The administration has several proposed rules that take on some aspect of the drug-pricing system, and is quietly talking with congressional Democrats on the issue, too.
- New rules should be finalized soon requiring drugmakers to include prices in their TV ads. The industry will likely sue.
- Conservatives are uneasy about Trump’s plan to import some European price controls, but Democrats may be willing to help.
The administration needs a win.
- Trump’s legal assault on the Affordable Care Act faces long odds and a backlash from congressional Republicans.
- Medicaid work requirements — the most substantive rightward shift the administration has imposed so far on health policy — have been struck down in court.
The bottom line: There will be headwinds on drug prices, too, but the general political climate and some alliance-building on Capitol Hill could easily make it a bright spot for the White House.